INFORMATION

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Application Number 10/661,366
Filing Date September 12, 2003
First Named Inventor Kerschbaumer, Randolf
Art Unit 1614
Examiner Name Not yet known
Attorney Docket Number 20695C-006400US

(use as many sheets as necessary) .

Sheet 1 of 4

U.S. PATENT DOCUMENTS+								
		Document Number		·				
Examiner Initials*	Cite No.	Number Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear			
MS	A1	US-4,395,396	07-26-1983	Eibl et al.				
MS	A2	US-4,873,316	10-10-1989	Meade et al.				
MS	A3	US-5,932,708	08-03-1999	Mertens et al.				
MS	A4	US-6,632,927 B2	10-14-2003	Adair et al.	•			
MS	.A5	US-6,391,299 B1	05-21-2002	Blackburn et al.				

			FOREIGN PA	TENT DOCUME	NTS	•	
Examiner	Cite	. For	eign Patent Document		Name of Patentee or	Pages, Columns, Lines, Where Relevant	
Initials*	No.1	Country Code ³ Number ⁴ kind Code ⁴ (If known)		Publication Date MM-DD-YYYY	Applicant of Cited Document	Passages or Relevant Figures Appear	T⁰
MS .	B1	PCT	WO 95/13300 A1	05-18-1995			
MS	B2	PCT	WO 97/26010. A1	07-24-1997			
MS	В3	PCT	WO 99/01476 A1	01-14-1999			

<u></u>		T	
Examiner		l Date	
Signature	/Michael Szperka/	Considered	08/11/2006
Co.g., a.c.		00110100100	00/11/2000

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Stind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language Translation is attached.

Substitute	for form 1449	в/РТО		Complete if Known		
INFORMATION DISCLOSURE				Application Number	10/661,366	
				Filing Date	September 12, 2003	
STATEMENT BY APPLICANT		First Named Inventor	Kerschbaumer, Randolf			
				Art Unit	1614	
(use as man	y sheets as	necessary) `	Examiner Name	Not yet known	
Sheet	2	of	4	Attorney Docket Number	20695C-006400US	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials *	Cite (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s) publisher, city and/or country where published.		
MS	C1	Ames, R.S. et al., "Conversion of Murine Fabs Isolated From a Combinatorial Phage Display Library to Full Length immunoglobulins", <i>J. immunol. Methods</i> , 1995, pp. 177-186.	
,	C2 ⁻	Bajaj, S. P. et al., A Monoclonal Antibody to Factor IX That Inhibits the Factor V111: Ca Potentiation of FactorX Activation, The Journal of Biological Chemistry, 260(21), pp. 11574-11580 (1985).	
	СЗ	Bessos, H., et al., The Characterization of a Panel of Monoclonal Antibodies to Human Coagulation Factor IX, Thrombosis Research, 40, pp. 863-867 (1985).	
	C4	Cao, Y. et al., Bispecific Antibodies as Novel Bioconjugates, Bioconjugate Chemistry, 9(6), pp. 635-644 (1998).	
	C5	Cohen, F.E., et al., The Combinatorial Approach, Protein Structure Prediction-A Practical Approach (Ed. M.J.E. Stemberg), Oxford University Press, Ch. 9, pp. 207-227 (1996).	
	C6	Engelhardt, O., et al., Two-Step Cloning of Antibody Variable Domains in a Phage Display Vector, Biotechniques, 17, p. 44-46 (1994).	
	C7	Esser, C., et al., Immunoglobulin Class Switching: Molecular and Cellular Analysis, Annu. Rev. Immunol., 8, p. 717-735 (1990).	
	C8	Evan, G. I., et al., Isolation of Monoclonal Antibodies Specific for Human c-myc Proto-Oncogene Product, Mol. Cell. Biol., 5(12), p. 3610-3616 (1985).	
	C9	Fay, P.J., et al., Factor Villa A2 Subunit Residues 558-565 Represent a Factor IXa Interactive Site, Journal of Biological Chemistry, 269(32), p. 20522-20527 (1994).	
	C10	Frazier, D., et al., Mapping of Monoclonal Antibodies to Human Factor IX, Blood, 74(3), p. 971-977 (1989).	
	C11	Gao, C., et al., Making Artificial Antibodies: A Format for Phage Display of Combinatorial Heterodimeric Arrays, Proc. Natl. Acad. Sci., 96, p. 6025-6030 (1999).	
	C12	Grassy, G., et al., Computer-Assisted Rational Design of Immunosuppressive Compounds, Nature Biotechnology, 16, p. 748-752 (1998).	
	C13	Greer, J., et al., Application of the Three-Dimensional Structures of Protein Target Molecules in Structure-Based Drug Design, Journal of Medicinal Chemistry, 37(8), p. 1035-1054 (1994).	
	C14	Harlow, E., et al., 2. Antibody Molecules, Antibodies-A Laboratory Manual; pp. 7-22 (1988).	
	C15	Harlow, E., et al., 3. Antibody-Antigen Interactions, Antibodies-A Laboratory Manual; p. 23-35(1988).	
MS	C16	Harlow, E., et al., 6. Monoclonal Antibodies, Antibodies-A Laboratory Manual; p. 139-243(1988).	

Examiner Signature	/Michael Szperka/	Date Considered	08/11/2006

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered, include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional), 2 Applicant is to place a check mark here if English language Translation is attached.

Substitute	for form 1449B/PT()		Complete if Known		
MEO	D14 A TION	DIC	OL OCUPE	Application Number	10/661,366	
INFORMATION DISCLOSURE				Filing Date	September 12, 2003	
STAT	EMENT B	Y AI	PPLICANT	First Named Inventor	Kerschbaumer, Randolf	
				Art Unit	1614	
(4	use as many she	ets as	necessary)	Examiner Name	Not yet known .	
Sheet	3	of	4	Attorney Docket Number	20695C-006400US	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
MS	C17	Hochuli, E., et al., Genetic Approach to Facilitate Purification of Recombinant Proteins with a Novel Metal Chelate Adsorbent, Biotechnology, 6, p. 1321-1325 (1988).	
	C18	Huston, J. S., et al., Medical Applications of Single-Chain Antibodies, Intern. Rev. Immunol., 10, p. 195-217 (1993).	
	C19	Jones, D.T., et al., Protein Folds and Their Recognition from Sequence, Protein Structure Prediction-A Practical Approach (Ed. M.J.E. Stemberg), Oxford University Press, Ch. 8,. p. 174-206 (1996).	
	C20	Jones, P.T., et al., Replacing the Complementarity-Determining Regions in a Human Antibody with Those from a Mouse, Nature, 321, p. 522-525 (1986).	
	C21	Jorquera, J. I., et al., Synthetic Peptides Derived from Residues 698 to 710 of Factor VtII Inhibit Factor. IXa Activity, Circulation, 86, Abstract No. 2725, p. 1-685 (1992).	
	.C22	Karpen, M.E., et al., Modelling Protein Conformation by Molecular Mechanics and Dynamics, Protein Structure Prediction-A Practical Approach (Ed. M.J.E. Stemberg), Oxford University Press, Ch. 10, p. 229-261 (1996).	
	C23	Kemp, D.S., Peptidomimetics and the Template Approach to Nucleation of B-sheets and a helices in Peptides, TIBTECH, 8, p. 249-255 (1990).	
	C24	Kerschbaumer, R.J. et al., Single-Chain Fv Fusion Proteins Suitable as Coating and Detecting Reagents in a Double Antibody Sandwich Enzyme-Linked Immunosorbent Assay, Analytical Biochemistry, 249, p. 219-227 (1997).	
	C25	Kerschbaumer, R.J., et al, pDAP2: A Vector for Construction of Alkaline Phosphatase Fusion Proteins, immunotechnology, 2, p. 145-150 (1996).	
	C26	Lane, R. D., A Short-Duration Polyethylene Glycol Fusion Technique for Increasing Production of Monoclonal Antibody-Secreting Hybridomas, Journal of Immunological Methods, 81, p. 223-227 (1985).	
	C27	Lenting, P.J., et al., The Sequence Gluf'f-Lys'd'd of Human Blood Coagulation Factor Vill Comprises a Binding Site for Activated Factor IX, Journal of Biological Chemistry, 271(4), p. 1935-1940 (1996).	
	C28	Liles, D. K., et al, The Factor VIII Peptide Consisting of Amino Acids 698 to 712 Enhances Factor IXa Cleavage of FactorX, Blood, 90(1), Abstract No. 2054, p. 463a (1997).	
	C29	Lin, H-F., et al, A Coagulation Factor IX-Deficient Mouse Model for Human Hemophilia B, Blood, 90(10), p. 3962-3966 (1997).	
	C30	Malik, P., et al., Multiple Display of Foreign Peptide Epitopes on Filamentous Bacteriophage Virions, Phage Display of Peptides and Proteins (Ed. B. K. Kay et al.), Academic Press, p. 127-139 (1996).	•
	C31	Mann, K.G., et al., Surface-Dependent Reactions of the Vitamin K-Dependent Enzyme Complexes, Blood, 76(1), p. 1-16 (1990).	
MS	C32	Mikaelsson, M., et al., Standardization of VIII:C Assays: A Manufacturer's View, Scandinavian Journal of Haematology (Ed. Nilsson et al.), 33, p. 79-86 (1984).	

Examiner Signature	/Michael Szperka/	Date Considered	08/11/2006	
-----------------------	-------------------	--------------------	------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.

Substitute	for form 1449	B/PTO		Complete if Known		
				Application Number	10/661,366	
			CLOSURE	Filing Date	September 12, 2003	
STAT	STATEMENT BY APPLICANT		First Named Inventor	Kerschbaumer, Randolf		
				Art Unit	1614	
(use as man	y sheets as	necessary)	Examiner Name	Not yet known	
Sheet	4	of	4	Attorney Docket Number	. 20695C-006400US	

		NON PATENT LITERATURE DOCUMENTS		
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		
MS	C33	Nilsson, I.M. et al., Induction of Split Tolerance and Clinical Cure in High-Responding Hemophi with Factor IX Antibodies, Proc. Natl. Acad. Sci. USA, 83, p. 9169-9173 (1986).		
	C34	PANKA et al. "Variable region framework differences result in decreased or increased affinity of variant anti-digoxin antibodies." <i>Proc. Natl. Acad. Sci. USA</i> , May 1988, pp. 3080-3084, Vol. 85, No. 9.		
	C35	Persic, L., et al., An Integrated Vector System For The Eukaryotic Expression of Antibodies or Their Fragments After Selection From Phase Display Libraries, Gene, p. 9-18 (1997).		
	C36	Pluckthun, A., et al., New Protein Engineering Approaches to Multivalent and Bispecific Antibody Fragments, Immunotechnology, 3, p. 83-105 (1997).		
4	C37	Raag, R., et al., Single-Chain Fvs, FASEB Journal, 9(1), pp. 73-80 (1995).		
	. C38	Rees, A.R., et al., Antibody Combining Sites: Structure and Prediction, Protein Structure Prediction-A Practical Approach (Ed. M.J.E. Stemberg), Oxford University Press, Ch. 7, p. 141-172 (1996).		
	C39 ,	Roitt, LM., et al., Molecules which Recognize Antigen, Immunology, 2nd Edition, p. 5.1-5.11(1989).		
	C40	RUDIKOFF et al. "Single amino acid substitution altering antigen-binding specificity." Proc. Natl. Acad. Sci. USA, 1982, pp. 1979-1983, Vol. 79, No. 6.		
	C41	Sadler, J.E., et al., Hemophilia A, Hemophilia B, and von Willebrand's Disease; The Molecular Basis of Blood Diseases (Ed. G. Stamatoyannopoulos et al.), p. 575-630 (1987).		
	C42	Vaughan, T.J., et al., Human Antibodies By Design, Nature Biotechnology, p. 535-539(1998).		
٠.	C43	Winter, G., et al., Making Antibodies by Phage Display Technology, Annu. Rev. Immunol., 12, p. 433-455 (1994).		
MS.	C44	Zhong, D., et al., Some Human Inhibitor Antibodies Interfere with Factor VIII Binding to Factor IX, Blood, 92(1), p. 136-142 (1998).		

Examiner Signature	/Michael Szperka/	Date Considered	08/11/2006
-----------------------	-------------------	--------------------	------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant:

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.